Pfizer announced positive results from the company’s comparative, confirmatory REFLECTIONS B538-02 study for the investigational monoclonal antibody PF-06410293, a potential Humira (adalimumab) biosimilar, saying that the study met primary objectives by demonstrating equivalent efficacy as measured by the American College of Rheumatology 20 (ACR20) response rate at week 12 in adult patients with moderate to severe arthritis.
The ACR20 response is defined as ≥20% improvement in tender joint count; ≥20% improvement in swollen joint count; and ≥20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (according to the disability index of the Health Assessment Questionnaire [HAQ]); and C-reactive protein (CRP).
The REFLECTIONS B538-02 trial is evaluating the efficacy, safety, and immunogenicity of PF-06410293 compared with Humira, with each being taken in combination with methotrexate when administered subcutaneously. REFLECTIONS B538-02 is a multinational, randomized, double-blind, two-arm, parallel group equivalence study conducted in 597 patients who have had an inadequate response to methotrexate therapy. The ongoing phase 3 study began in June 2015 and is expected to be completed in December 2017.
Sumant Ramachandra, MD, PhD, MBA, Head of Research and Development, Pfizer Essential Health, said the positive study results for PF-06410293 build on the company’s robust biosimilar pipeline, which consists of eight distinct biosimilar molecules in mid- to late-stage development and several others in early-stage development.
The newest data from PF-06410293 represent Pfizer’s second proposed biosimilar for inflammatory conditions and third proposed biosimilar pipeline molecule to report positive top-line results within the past 4 months.
Spanish Real-World Study: Adalimumab Biosimilar MSB11022 Safe, Effective in IBD
May 18th 2024A real-world study in Spain on inflammatory bowel disease (IBD) patients found no meaningful changes in clinical or biochemical markers or differences in effectiveness between the adalimumab originator and the biosimilar MSB11022 (Idacio; Fresenius Kabi) in adalimumab-naïve patients.
Insights from Festival of Biologics: Dracey Poore Discusses Cardinal Health’s 2024 Biosimilar Report
May 19th 2024The discussion highlighted key emerging trends from the Festival of Biologics conference and the annual Cardinal Health Biosimilars Report, including the importance of sustainability in the health care landscape and the challenges and successes in biosimilar adoption and affordability.
Panelists Call for Consistent Education, Support to Improve Patient Comfort With Biosimilars
May 15th 2024At the Festival of Biologics USA, panelists stressed the need for patient-centered communication and education to boost comfort with biosimilars, emphasizing consistent support from health care providers despite restrictive payer policies.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Survey Finds Korean Oncologists Trust Biosimilars But Prescribe Originators More
May 13th 2024A Korean survey found that while most oncologists believe biosimilars are just as safe and effective as originator drugs, they often prescribe the originators due to factors like lack of patient trust in biosimilars and lower than expected cost savings.
Patients With IBD Experience Nocebo Effect Post Mandatory Switch to Biosimilar
May 11th 2024In Canada, a study on patients with inflammatory bowel disease (IBD) switching to infliximab or adalimumab biosimilars found no change in clinical remission or antidrug antibodies after 24 weeks, but 13% experienced the nocebo effect, leading to one-fifth discontinuing therapy.